株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

体外診断検査の世界市場:第10版

The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition

発行 Kalorama Information 商品コード 235126
出版日 ページ情報 英文 1000 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
体外診断検査の世界市場:第10版 The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition
出版日: 2016年08月22日 ページ情報: 英文 1000 Pages
担当者のコメント
1997年第1版の発売以来、約2年毎にアップデート版を発行し、2016年8月に第10版を発行、発売開始致しました。19年間にわたる世界の体外診断市場リサーチを行なうカロラマインフォメーション社の当調査レポートは、今やIVD調査のグローバルスタンダードとも言え、世界中のIVD関連企業が活用するベストセラーレポートです。第10版はプレイヤープロファイルも含め約1700ページの情報量となっています。
概要

当レポートでは、世界の体外診断 (IVD) 検査の市場を調査し、人口および疾患統計などの市場背景、市場全体における主な動向とイノベーション、検査技術・検査対象別の詳細分析、主要な関連事業者の分析などをまとめています。

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 世界の体外診断 (IVD) 市場:概要

  • 背景
  • 世界の人口および疾病統計
  • 市場促進因子としての新興市場
  • 世界のIVD市場の区分とIVD市場の発展
  • 特定国の情報
  • 米国
  • 日本
  • 欧州
  • 中国
  • インド
  • ブラジル
  • ロシア
  • カナダ
  • サウジアラビア
  • アジア地域のレビュー

第4章 各種動向・革新

  • 背景
  • パーソナルゲノム研究の進歩
  • シーケンシングの臨床への移行
  • デジタルテクノロジー・IT・ビッグデータ
  • 遺伝子編集
  • ウェアラブルデバイス
  • 呼気検査の進歩

第5章 ポイントオブケア(POC)検査

  • 概要・動向
  • プロフェッショナルPOC
  • OTC自己検査
  • 大腸癌スクリーニング
  • 脂質検査
  • 主なPOC検査企業
  • 糖尿病検査:血糖モニタリング
  • 血糖値検査と厳しい経済状況
  • 糖尿病管理を支援するIT
  • 糖尿病市場の分析
  • 血糖値の自己検査
  • 非侵襲的検査デバイス
  • 連続的自己検査と人工膵臓
  • プロフェッショナルによる血糖値検査
  • 糖尿病検査 - グリコヘモグロビン
  • 遺伝子・その他の糖尿病マーカー

第6章 コアラボ

  • コアラボの概要・動向
  • コネクティビティ
  • 化学検査の概要
  • ラボオートメーション
  • 市場分析
  • ラピッドレスポンスシステム
  • クリティカルケアの分析
  • ユーザーアプリケーション
  • 尿検査
  • コアラボの商業的展望

第7章 免疫測定

  • 概要・動向
  • 免疫測定技術の持続的発展
  • 質量分析
  • コアラボにおける免疫測定
  • 放射免疫測定
  • 市場分析
  • 主要サプライヤーと成長の潜在性
  • 成熟期のアッセイ区分
  • 甲状腺機能
  • 治療薬モニタリング
  • 貧血
  • 毒性学/DAU
  • アレルギー
  • 成熟化する免疫測定
  • タンパク質
  • 成長期の免疫測定
  • ビタミンD
  • 腫瘍マーカー
  • 心臓マーカー
  • 自己免疫
  • 関節リウマチ
  • 胃腸障害
  • 移植臓器管理
  • 女性の健康
  • アルツハイマー病
  • その他
  • ポイントオブケアOTCと専門家による利用
  • 妊娠検査
  • 心臓血管系の診断
  • 薬物乱用/治療薬モニタリング
  • 免疫測定の商業的展望

第8章 分子アッセイ

  • 概要
  • サンプル調製と品質管理
  • 先進分子検査・技術
  • エキソソームシーケンシング
  • リキッドバイオプシー
  • メタボロミックプロファイリング
  • 検査価値のためのIT
  • 法医学研究:新しい市場機会
  • 検査プラットフォーム
  • 主要企業
  • 市場分析
  • 遺伝性疾患
  • 出生前・新生児検査
  • 組織タイピング
  • 分子検査の商業的展望

第9章 血液学

  • 血液学の概要・動向
  • デジタル画像分析
  • デジタルの進化
  • 分散型血液検査
  • POCにおけるヘモグロビン/ヘマトクリット
  • 市場分析:主要サプライヤー
  • 血液検査の商業的展望

第10章 凝固

  • 凝固および免疫血液検査の概要
  • 直接経口抗凝固薬 (DOAC)
  • Dダイマー
  • 市場分析
  • ラボベースの検査
  • 高凝血異常 (hypercoagulopathy) の遺伝子マーカー
  • 分散型凝固検査:専門家による利用
  • 分散型凝固検査:OTC
  • 血小板検査
  • 主要サプライヤー
  • 凝固検査の商業的展望

第11章 微生物学およびウィルス学

  • 概要
  • 特定トピック
  • いくつかの疾病のデータ
  • 妊娠中の感染:ジカなど
  • 新しい病気の脅威
  • 抗菌薬耐性
  • 幻想ではない質量分析法
  • 感染症スクリーニング用血清
  • マイクロバイオーム - 疾患過程におけるバクテリア
  • 市場分析
  • 消耗品
  • 発色性媒体
  • 微生物同定および抗菌薬の感受性試験
  • 微生物学とオートメーション
  • 血液培養
  • ラピッドテスト
  • 免疫測定 - ラボベース
  • 免疫測定 - ラピッド
  • 分子検査
  • 微生物/ウィルス検査の商業的展望

第12章 血液バンクサービス

  • 概要・動向
  • 輸血の有効性
  • 人工血液
  • 病原体への警告
  • 血小板の安全性
  • 市場分析
  • 血液のグループ化とタイピング
  • 免疫測定
  • 核酸検査 (NAT)
  • 血液バンクの商業的展望

第13章 組織学および細胞学

  • 概要
  • 特定トピック
  • 組織学とオートメーション
  • 先進分析ソリューション
  • HPVはコアラボに
  • 市場分析
  • 組織学と細胞学
  • 免疫組織化学およびIn Situハイブリダイゼーション
  • ファーマコダイアグノスティクスの組織学
  • デジタル画像とコンピューターによる病理学
  • 循環腫瘍細胞
  • フローサイトメトリー
  • 組織・細胞検査の商業的展望

第14章 企業プロファイル:トップティア

第15章 企業プロファイル:第2ティア

第16章 企業プロファイル:血液バンク専門企業

第17章 企業プロファイル:凝析専門企業

第18章 企業プロファイル:コアラボおよびその他の企業

第19章 企業プロファイル:CTC・リキッドバイオプシー検査プロバイダー

第20章 企業プロファイル:糖尿病専門企業

第21章 企業プロファイル:血液 (細胞分析) 専門企業

第22章 企業プロファイル:病理組織専門企業

第23章 企業プロファイル:免疫測定専門企業

第24章 企業プロファイル:IT専門企業

第25章 企業プロファイル:微生物専門企業

第26章 企業プロファイル:分子検査専門企業

第27章 企業プロファイル:POC専門企業

第28章 企業プロファイル:出生前診断サービスプロバイダー

第29章 企業プロファイル:品質管理・試料前処理専門企業

第30章 企業プロファイル:検査サービスプロバイダー

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI15067157

This Kalorama Information report, The Worldwide Market for In Vitro Diagnostic Tests, has been updated for two decades in ten editions, keeping readers informed about developments in all areas of IVD, around the world, in one volume. The 1,600-page report provides market size estimates and projections for the entirety of the clinical diagnostics testing market. It also tracks hundreds of competitors, notes significant partnerships, distribution deals and acquisitions and defines the market share situation for the IVD market and competitive analysis for many segments.

Market Size and Forecast for All IVD Market Segments

Published every two years, this report estimates current market size and forecasted market size to 2021 for defined segments of the IVD market and various sub-segments, including:

  • Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
  • Clinical Chemistry and "Core Lab" Markets (including sub segment revenues for General Chemistries, Workstations, Analyzers Blood Gases, Urinalysis, Critical Care)
  • Point-of-Care Testing (POC), (Professional and Self-Testing, Glucose Testing, Pregnancy Tests, drugs of abuse, HIV, H. pylori, Other, OTC/Self Total, Professional POC, Cardiac Markers, Drugs of Abuse, HbA1c, Pregnancy, Other)
  • Microbiology and Virology by Test Type (Immunoassays, ID/AST, Infectious Diseases - DNA; ID/AST: Panels and Reagents, automated; Panels and Reagents, manual; Blood Culture; Chromogenic Media; Rapid Micro; Supplies)
  • Blood Banking (Grouping, Immunoassay Screens, NAT Screens)
  • Tissue-Based Testing - Histology and Cytology (Pap, ISH, IHC, HPV)
  • Infectious Disease Immunoassay Testing (Hepatitis, HIV, STDs, TORCH, Respiratory, Sepsis, Parasitology, Mycology, Others)
  • Hematology
  • Molecular Tests in Infectious Diseases (HAI, HIV, Hepatitis, GC/Chlamydia, Respiratory, Organism ID, Mycobacteria, TB, Others
  • Non-Infectious Disease Immunoassay Sales by Analyte Type (Cardiac markers, Tumor markers, Diabetes/HbA1c, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic drugs, Tox/Drugs of abuse, Vitamin D)
  • Coagulation Tests (Lab-Based, POC, Genetic Markers)
  • Sequencing and Flow Cytometry

No other report provides similar understanding of the world diagnostics market. For each of the listed segments, 2016 market size, 2021 projection and compound annual growth rate is provided, as well as significant companies in the market and product innovations. The market data is put into a context with real-world industry and medical practice trends. Shara Rosen (MBA, RT), has authored ten editions of this superior work intended to provide IVD market coverage in a world perspective. The report has been called "The Bible of the IVD Industry" by customers, which include top IVD firms. Using Kalorama Information's report ensures that your firm will have the perspective and data of others in the industry and those that track the industry and invest in it.

Regional and Country IVD Markets Defined

In vitro diagnostics is a global market and the report reflects the global scope. Companies sell globally and think globally. Trends in one part of the world affect product decisions and company financial performance in others. Thus, this is a global report and the following regional and country overall IVD markets are included:

  • US
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Netherlands
  • Turkey
  • Poland
  • Canada
  • China
  • Japan
  • Saudi Arabia
  • Brazil
  • Latin America
  • Eastern Europe
  • Emerging Markets
  • Rest of World

The Worldwide Market for In Vitro Diagnostic Tests is a testament to the Kalorama methodology. It is the result of months of painstaking work by an experienced IVD industry analyst, who has tracked hundreds of companies for developments, trends and financial results. This research is compiled along with the opinion, observations and insights of industry experts to produce an unparalleled vision of the industry as it is in 2016.

Superior Company Profiling

The report concentrates over a thousand pages on detailed and tiered profiles of companies in the in vitro diagnostics markets. The experience that Kalorama Information has in this market is evident in its tiering and segmentation of companies.

Top Tier Companies: These are the dominant companies in IVD. For each company, extensive, discussion of recent financial performance is provided. Their main products are detailed and any significant company strategies, partnerships and acquisitions are considered:

  • Abbott Diagnostics
  • Alere Inc
  • Beckman Coulter, Inc. / Danaher
  • Becton, Dickinson and Company (BD)
  • bioMérieux Inc.
  • Bio-Rad Laboratories
  • Hologic
  • Instrumentation Laboratory (IL)
  • Ortho Clinical Diagnostics (OCD)
  • QIAGEN N.V
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo FisherScientific
  • Werfen Group S.A.

Next Tier IVD Companies:

Growth-oriented companies that have significant presence in one or several areas are profiled and their new products and strategies discussed in the report. Among these:

  • Affymetrix Inc.
  • Cepheid
  • ERBA Diagnostics, Inc
  • DiaSorin S.p.A
  • Illumina
  • Luminex Corporation
  • Menarini Diagnostics.
  • Mindray Medical International Limited
  • Myriad Genetics
  • Perkin Elmer, Inc. (PE)
  • Quidel Corporation
  • Randox Laboratories Ltd
  • Royal Philips
  • TOSOH Corporation
  • Trinity Biotech
  • Wako Pure Chemical Industries

Specialist Companies:

While these companies focus on one segment of the IVD market, they can often be dominant in the They are important to watch because they can often develop products in new areas of testing and move categories.

  • Molecular Specialists
  • Blood Banking Specialists
  • Point of Care Specialists
  • Prenatal Test Service Providers
  • Quality Control and Pretreatment Specialists
  • CoagulationSpecialists
  • Histology and Cytology Specialists
  • Microbiology Specialists
  • IT SolutionsCompanies
  • CTC and Liquid Biopsy Specialists

Deep Understanding of IVD Market Trends

Published continuously for two decades, the report reflects the experience Kalorama has in watching events in IVD and the emergence and reemergence of industry, technological and clinical trends. For instance:

  • The revolution in bioinformatics is allowing clinical and traditional medical engineering to blend with components derived from the telecommunications, information and computer sciences industries. This opens new niche markets for POC test devices, which will have a positive impact on diagnostic testing.
  • Getting information to care givers and patients is now not an added plus, it is a prerequisite of all lab operations. Thus the next 3-5 years will see an intensification of the healthcare industry's emphasis on informatics, wireless communications, data networking and cost/effective healthcare delivery.
  • In the area of test economics, outcomes based disease management establishes guidelines and directives for patient care. This is having a significant effect on the use of new tests, which have to prove their added value to patient care. It also affects how many and which tests are recommended and thus reimbursed for a specific disease group.

None of the above would be happening without significant forces in the market driving them. This updated report presents the trends, technologies, customer needs and major suppliers with an eye on how they are shaping the IVD industry, including the following trends:

  • Top 20 Companies and Niche Players 2012-2016
  • Acquisitions in the IVD Market
  • NGS, LC-MS and Other Novel Testing
  • Lab Market Segmentation (Hospital, Independent, POLs)
  • Emerging Markets
  • Digital Technology, IT and Big Data
  • Gene Editing
  • Wearables
  • Europe and Austerity
  • Status of LDTs
  • State of Biomarker Discovery
  • Test Services Trend
  • Distribution Agreements
  • Role of Sequencing
  • Non-Blood Sampling
  • LDT Regulatory Picture
  • New Product Launches
  • Near-Patient Testing
  • DTC Testing
  • New Testing Venues

The Most Comprehensive Picture of Today's IVD Industry

In addition to providing superior business planning tools, the following are among the many topics that the report tackles:

  • 20 Years of IVD: A summary of the IVD industry from 1995 to the present. Amazingly a lot has changed - new tests and technologies have come to market but the very same major companies generate about 90% of product sales.
  • Demographics: A number of world events bode well for the future of medical devices: an aging worldwide population and demand for new hospitals in developing countries.Increasing numbers of people between the ages of 45 and 75 years in the industrialized world consume more healthcare services such as heart and cancer tests. IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and growing demands for quality medical care. The next five to ten years or so will see moderate and gradual change in IVD product markets.
  • Changing Core Lab: Not 10-15 years ago most microbiology and anatomic pathology labs were tucked away somewhere in the basement. The major test areas similarly were separated by impenetrable walls. Those days aregone: imagine a centralized hospital lab where clinical chemistry, immunoassays, hematology, coagulation, urinalysis, some microbiology, some cytology tests are all performed in one room and often on instrumentation that are linked by an automated track line and all in the same room. More importantly by a lab information system that consolidates test results to an electronic patient record.
  • Emerging Markets: High growth countries, primarily Saudi Arabia, Brazil, China and India experience market growth of double digits. This is fueled by privatization and health insurance initiatives by governments and employers. However this growth has a negligible effect to compensate for the lack of significant growth in major markets of Europe, Japan and the U.S.
  • IVD-Focused Government Initiatives: New healthcare disease screening and health insurance initiatives proposed by the new U.S.administration under the guidance of President Barack Obama further bolster the use of IVDs, but continued economic difficulties has U.S. citizens forgo elective procedures because the co-payments may be somewhat unaffordable.
  • Automation: There is also a lack of trained lab technologists, so there is a decreasing availability of human resources needed to run the more complex new set of molecular and histological tests and immunoassays. Therefore there has been a proliferation of test and lab automation tools launched that remove precious human resources from mundane pre-analytical and sample-tracking tasks to make time for more sophisticated ones. This phenomenon was once thought to be the purview of core lab biochemistry and immunoassays but automation is becoming a common feature hematology, blood banking,microbiology, and histology. Demand for healthcare and thus diagnostic tests in all the major markets is driven by aging populations and increased incidence of conditions such as: cancer, diabetes,cardiovascular disease, arthritis and obesity.In light of the demand for these tests, they have been reformulated for automated analyzers where the cost per test is traditionally low.
  • New Sampling: No more blood sampling: be prepared for an IVD world of breath tests for conditions that includes respiratory infections,gastrointestinal disorders, cancer and even chronic diseases. Wearable patch sensors have been commercialized for glucose and vital signs monitoring; more and more applications are in development.
  • Sequencing Enters the Clinic: In the 21st century, understanding a patient's personal genomic profile equips physicians with valuable information to better diagnose, predict, treat and prevent disease. Personalized medicine using genomic information improves patient outcomes and reduces healthcare costs and adverse drug reactions. The NGS data analysis market includes the market by product (software and services) and by applications such as whole genome sequencing, exome sequencing, targeted re-sequencing, de novo sequencing, RNA-Seq, ChIP-Seq and Methyl-Seq. As experience with sequencing intensifies, researchers are beginning to discover some of the ways in which the technology can be used. It is generally anticipated that whole genome sequencing is most appropriate for broad research looking for linkages between gene mutations and disease development.

These and many more topics are covered in The World Market for In Vitro Diagnostic Tests, 10th Edition. We publish other specific reports in molecular diagnostics, U.S. IVD, companion diagnostics and next generation sequencing and many others. Our entire library of reports are available via our Knowledge Center service at considerable savings and convenience for your company. Order your copy today.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Scope and Methodology
  • Size and Growth of the Market
  • Market Trends

TWO: INTRODUCTION

  • Report Design
  • Lab Medicine Disciplines and Applications
  • Market Analysis of IVD Market Segments
  • IVD Companies Mix and Match
  • Distribution Agreements
  • Licenses and Collaboration agreements
  • Test Services
  • Top Suppliers and Niche Players
  • IVDs Then and Now - A 20 Year Perspective
  • In the Beginning to Now
  • Surprises and Disappointments
  • Future
  • Point of View

THREE: OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC MARKETS

  • Background
  • Population and Disease Demographics Worldwide
  • Emerging Markets as a Market Driver
  • World Segments of the IVD Market and IVD Market Evolution
  • Specific Country Information
  • The United States of America
  • Japan
  • Europe: Slow Growth - Effects of Austerity
  • IVD Directive Update
  • China
  • India
  • Brazil
  • Russia
  • Canada
  • Saudi Arabia
  • Asia Review

FOUR: TRENDS AND INNOVATION

  • Background
  • Personal Genomics - A Work in Progress
  • Sequencing Enters the Clinic
  • Digital Technology, IT, BIG Data
  • Gene Editing
  • Wearables
  • Breath Test Advances

FIVE: POINT-OF-CARE TESTS

  • Overview and Trends
  • Professional POC
  • OTC Self Testing
  • Colon Cancer Screening
  • Lipid Testing
  • The Major POC Test Players
  • Diabetes Testing - Blood Glucose Monitoring
  • Glucose Testing in Tight Economics
  • IT to Aid Diabetes Management
  • Diabetes Market Analysis
  • Blood Glucose Self-Testing
  • Noninvasive Testing Devices
  • Continuous Self Testing en Route to the Artificial Pancreas
  • Blood Glucose Testing by Professionals
  • Diabetes Testing - Glycated Hemoglobin
  • Genes and Other Markers of Diabetes

SIX: THE CORE LAB

  • Core Lab Overview and Trends
  • Connectivity
  • Overview of Chemistry Tests
  • Lab Automation
  • Market Analysis
  • Rapid Response Systems
  • Critical Care Analysis
  • User Apps
  • Urinalysis
  • The Commercial Outlook for Chemistry Tests

SEVEN: IMMUNOASSAYS

  • Overview and Trends
  • Immunoassay Technology Continues to Evolve
  • Mass Spectrometry
  • Immunoassays in the Core Lab
  • Radioimmunoassays
  • Market Analysis
  • Leading Suppliers and Growth Potential
  • Mature Assay Segment
  • Thyroid Function
  • Therapeutic Drug Monitoring
  • Anemia
  • Toxicology/DAU
  • Allergy
  • Maturing Immunoassays
  • Proteins
  • Growth Immunoassays
  • Vitamin D
  • Tumor Markers
  • Cardiac Markers
  • Autoimmune
  • Rheumatoid Arthritis
  • Gastrointestinal Disorders
  • Transplant Management
  • Women's Health
  • Alzheimer's Disease
  • Miscellaneous
  • Point-of-Care OTC and Professional Use
  • Pregnancy Testing
  • Cardiovascular Diagnostics
  • Drugs of Abuse/Therapeutic Drug Monitoring
  • The Commercial Outlook for Immunoassays

EIGHT: MOLECULAR ASSAYS

  • Overview
  • Sample Preparation and Quality Control
  • Advanced Molecular Tests and Technologies
  • Exosome Sequencing
  • Liquid Biopsy
  • Metabolomic Profiling
  • Information Technology for Test Value
  • Forensic Studies - An Emerging Opportunity
  • Test Platforms
  • Major Players
  • Market Analysis
  • Oncology
  • Inherited Diseases
  • Prenatal and Newborn Testing
  • Tissue Typing
  • The Commercial Outlook for Molecular Tests

NINE: HEMATOLOGY

  • Overview of Hematology and Trends
  • Digital Image Analysis
  • Digital Evolution
  • Decentralized Hematology Testing
  • Hemoglobin/Hematocrit at the POC
  • Market Analysis: Leading Suppliers
  • The Commercial Outlook for Hematology Tests

TEN: COAGULATION

  • Overview and Trends of Coagulation and Immunohematology Tests
  • Special Topics
  • Direct Oral Anticoagulants (DOACs)
  • D-dimer
  • Market Analysis
  • Lab-based Testing
  • Genetic Markers of Hypercoagulopathies
  • Decentralized Coagulation Testing - Professional Use
  • Decentralized Coagulation Testing - OTC
  • Platelet Testing
  • Leading Suppliers
  • The Commercial Market for Coagulation Tests

ELEVEN: MICROBIOLOGY AND VIROLOGY

  • Overview
  • Special Topics
  • Some Disease Facts
  • Pregnancy Infections - Beyond Zika
  • Emerging Disease Threats
  • Antimicrobial Drug Resistance
  • Mass Spectrometry Not a Pipedream
  • Infection Screening Serology
  • Microbiome - Bacteria in Disease Processes
  • Market Analysis
  • Supplies
  • Chromogenic Media
  • Microbial Identification and Antimicrobial Sensitivity Tests
  • Automated Microbiology
  • Blood Culture
  • Rapid Tests
  • Immunoassays - Lab-based
  • Immunoassays - Rapid
  • Molecular Tests
  • The Commercial Outlook for Microbiology / Virology Tests

TWELVE: BLOOD BANKING SERVICES

  • Overview and Trends
  • are all these transfusions good medicine
  • Artificial blood
  • Pathogen Alerts
  • Platelet Safety
  • Market Analysis
  • Blood Grouping and Typing
  • Immunoassays
  • Nucleic Acid Testing (NAT)
  • The Commercial Outlook for Blood Banking

THIRTEEN: HISTOLOGY AND CYTOLOGY

  • Overview
  • Special Topics
  • Histology Automation
  • Advanced Analysis Solutions
  • HPV Goes Core Lab
  • Market Analysis
  • Histology/Cytology
  • Immunohistochemistry and In Situ Hybridization
  • Pharmacodiagnostic Histology
  • Digital Imaging and Computational Pathology
  • Circulating Tumor Cells
  • Flow Cytometry
  • The Commercial Outlook for Histology and Cytology Tests

FOURTEEN: COMPANY PROFILES: THE TOP TIER

  • Abbott Diagnostics
  • Recent Revenue History:
  • 2014/2015 Business Highlights
  • Core Lab
  • Immunoassays
  • Hematology
  • Coagulation
  • Blood Bank
  • Point of Care
  • Diabetes
  • Molecular
  • IntelligentMDx Alliance
  • PLEX-ID
  • Iridica
  • Histology
  • Alere Inc
  • Recent Revenue History:
  • Alere in Africa
  • Product News
  • Microbiology
  • Molecular
  • Arkray
  • Recent Revenue History:
  • Urinalysis
  • Diabetes
  • Molecular
  • Beckman Coulter, Inc. / Danaher
  • Recent Revenue History:
  • Core Lab
  • Hematology
  • Immunoassays
  • Iris International
  • Microbiology
  • Molecular
  • Sequencing
  • Genomics
  • Information Technology
  • Flow Cytometry
  • Becton, Dickinson and Company (BD)
  • Recent Revenue History:
  • Traditional Microbiology
  • Blood Culture
  • Mass Spectrometry
  • Veritor System - Immunoassays
  • Histology
  • HPV
  • Molecular
  • The BD MAX Enterprise
  • Sequencing
  • Flow Cytometry
  • bioMérieux Inc
  • Recent Revenue History:
  • Traditional Microbiology
  • Blood Culture
  • Immunoassays
  • Rapid Tests
  • Oncology
  • Mass Spectrometry
  • Molecular Strategy
  • Sequencing Service
  • Expansion
  • Bio-Rad Laboratories, Inc
  • Recent Revenue History
  • Controls
  • Diabetes
  • Blood Bank
  • Immunoassays
  • Flow Cytometry
  • Digital PCR
  • Danaher Corporation
  • Recent Revenue History
  • Hologic, Inc
  • Recent Revenue History:
  • The Gen-Probe/PANTHER Business
  • Blood Bank
  • Quest Contract
  • Instrumentation Laboratory (IL)
  • Recent Revenue History: ($ millions)
  • Coagulation
  • Direct Oral Anticoagulant Testing (DOAC)
  • Coagulation Automation
  • Critical Care
  • Ortho Clinical Diagnostics (OCD)
  • Recent Revenue History:
  • Blood Bank
  • QIAGEN N.V
  • Recent Revenue History
  • Tuberculosis
  • Infectious Disease Testing
  • Transplant Medicine and HAIs
  • Personalized Healthcare
  • Companion Diagnostics
  • Liquid Biopsy/CTC
  • Instrumentation Base
  • Rotor-Gene Q - Clinical Diagnostics
  • Sequencing
  • Exosomes
  • Information Technology
  • Collaborations
  • Forensics
  • Radiometer A/S
  • Recent Revenue History:
  • Immunoassays
  • Hemocue AB
  • Roche Diagnostics
  • Recent Revenue History
  • New Enterprises
  • Global Access Program for HIV
  • Core Lab
  • Hematology
  • Immunoassays
  • Transplant Medicine
  • Diabetes
  • Point of Care
  • Core Molecular Tests
  • Virology
  • STDs
  • A POC Enterprise - Liat
  • Prenatal and cfDNA
  • HPV
  • Blood Bank
  • Liquid Biopsy
  • Personalized Medicine
  • Sequencing - Putting the Pieces Together
  • Siemens Healthcare Diagnostics
  • Recent Revenue History:
  • Core Lab
  • Immunoassays
  • Urinalysis
  • Critical Care
  • POC Connectivity
  • Hematology
  • Histology
  • Coagulation
  • Molecular
  • Companion Diagnostics
  • China
  • Sysmex Corporation
  • Recent Revenue History:
  • Hematology
  • Coagulation
  • Core Lab
  • Inostics GmbH
  • Flow Cytometry
  • Thermo Fisher Scientific Inc
  • Recent Revenue History:
  • Sequencing
  • Microbiology
  • Microbiology IT
  • Transplant
  • Quality Control
  • Mass Spectrometry
  • Point of Care
  • Molecular
  • Oncology
  • Forensic
  • Werfen Group S.A

FIFTEEN: Company Profiles: The Second Tier

  • Affymetrix Inc
  • Recent Revenue History
  • Axiom Genotyping Applications
  • Agilent Technologies
  • Recent Revenue History:
  • Agilent in Genomics
  • PCR
  • Sequencing
  • Arrays
  • Cepheid
  • Recent Revenue History:
  • Hospital Acquired Infections (HAI)
  • TB
  • Infectious Diseases
  • Virology
  • Oncology
  • Eiken Chemical Co., Ltd
  • Recent Revenue History:
  • ERBA Mannheim
  • ERBA Diagnostics, Inc
  • Recent Revenue History:
  • Product Expansion
  • DiaSorin S.p.A
  • Recent Revenue History:
  • Immunoassays
  • Molecular
  • Fujirebio Diagnostics, Inc
  • Recent Revenue History:
  • Molecular
  • Illumina
  • Recent Revenue History:
  • Understand Your Genome Symposium
  • Sequencing
  • Sequencing Kits
  • Sample Prep
  • IVD Business
  • Oncology
  • HLA Typing
  • Information Technology
  • CRISPR
  • Forensics
  • CLIA Lab Service
  • Sample to Insight
  • Making a Market
  • Expansion in China
  • LabCorp, Laboratory Corporation of America
  • Recent Revenue History:
  • Infectious Diseases
  • Prenatal
  • Sequencing
  • Oncology
  • Information Technology
  • Forensic
  • Expanding Food Testing
  • Luminex Corporation
  • Recent Revenue History: $ million
  • Business Expansion
  • MAGPIX Multiplexing
  • Next Generation NxTag
  • Menarini Diagnostics
  • Recent Revenue History:
  • Mindray Medical International Limited
  • Recent Revenue History:
  • Core Lab
  • Hematology
  • Coagulation
  • Myriad Genetics
  • Recent Revenue History: (millions)
  • Molecular Product News
  • Beyond Cancer
  • IP Update
  • PerkinElmer, Inc. (PE)
  • Recent Revenue History: ($ million, estimated)
  • Newborn Testing
  • Prenatal Testing
  • Histology
  • Information Technology
  • India
  • China
  • Quest Diagnostics
  • Recent Revenue History:
  • Oncology
  • Infectious Diseases
  • Prenatal and Women's Health
  • Market Expansion
  • Insurance and Wellness Business
  • Quest Partners for Market Accessibility
  • Information Technology
  • Quidel Corporation
  • Recent Revenue History:
  • Point of Care
  • Immunoassays
  • Molecular
  • Lyra Product Line
  • Solana Molecular System
  • AmpliVue Product Line
  • Savanna (formerly Wildcat)
  • Randox Laboratories Ltd
  • Recent Revenue History:
  • Controls
  • Immunoassays
  • Molecular
  • Prenatal
  • POC
  • Royal Philips
  • Histology
  • Point of Care
  • TOSOH Corporation
  • Recent Revenue History: (
  • Immunoassays
  • Transasia Bio-Medicals Ltd
  • Trinity Biotech plc
  • Recent Revenue History: $ million
  • Wako Pure Chemical Industries, Ltd
  • Recent Revenue History

SIXTEEN: COMPANY PROFILES: BLOOD BANK SPECIALISTS

  • BloodSource
  • Cerus Corporation
  • Recent Revenue History
  • Grifols
  • Recent Revenue History:
  • Clinical Analysis
  • Blood Transfusion Business
  • International Programs
  • Molecular
  • Haemokinesis Pty Ltd
  • Immucor, Inc
  • Recent Revenue History
  • Transfusion Medicine
  • Transplant Diagnostics
  • IMMUCOR DX Laboratory Service
  • Micro Typing Concepts (MTC)
  • Quotient Limited
  • Recent Revenue History
  • Traditional Blood Grouping
  • MosaiQ Platform

SEVENTEEN: COMPANY PROFILES: COAGULATION SPECIALISTS

  • Diagnostica Stago, S.A.S
  • Recent Revenue History
  • Instrumentation
  • Test Kits
  • Microvisk Technologies

EIGHTEEN: COMPANY PROFILES: CORE LAB AND OTHER COMPANIES

  • AB SCIEX Pte Ltd
  • Bruker BioSciences Corporation
  • Recent Revenue History
  • Microbiology
  • Tissue Analysis
  • EKF Diagnostics Holdings Plc
  • Recent Revenue History
  • Lab-based Assays
  • Molecular
  • EliTech Group S.A.S
  • MedTest DX
  • Microsaic Systems plc
  • Nova Biomedical
  • Diabetes
  • Scienion AG
  • Sekisui Diagnostics
  • Shimadzu Scientific Instruments
  • Tecan Group
  • Recent Revenue History

NINETEEN: COMPANY PROFILES: CTC & LIQUID BIOPSY TEST PROVIDERS

  • Angle plc
  • ApoCell, Inc
  • Biocept, Inc
  • Recent Revenue History
  • Menu Expansion
  • Reimbursement
  • Biodesix, Inc
  • Celsee Diagnostics (formerly DeNovo Sciences, Inc.)
  • Circulogene Theranostics
  • Clearbridge BioMedics
  • Cynvenio Biosystems, Inc
  • Epic Sciences Inc
  • Collaborations
  • Exosome Diagnostics, Inc
  • Fluxion Biosciences, Inc
  • Genyo - Centre for Genomics
  • Janssen Diagnostics, LLC (formerly Veridex, LLC)
  • Recent Revenue History
  • Menarini-Silicon Biosystems
  • Qiagen Hanover
  • Recent Revenue History
  • ScreenCell
  • WaveSense LLC

TWENTY: COMPANY PROFILES: DIABETES SPECIALISTS

  • Animas Corporation
  • Recent Revenue History
  • Ascensia Diabetes Care (formerly Bayer Diabetes Care)
  • Recent Revenue History
  • Bigfoot Biomedical
  • Cellnovo Group
  • Recent Revenue History
  • Debiotech SA
  • DexCom, Inc
  • Recent Revenue History
  • Dexcom Product Overview
  • Collaborations
  • Diasend AB
  • Recent Revenue History
  • Gentag, Inc
  • Gentag's Patent Position
  • Glucosense Diagnostics Ltd
  • Glysure Limited
  • Glytec Inc
  • iHealth Lab Inc
  • Insulet Corporation
  • Recent Revenue History
  • Neighborhood Diabetes Inc
  • Integrity Applications Inc
  • LabStyle Innovations Corp
  • Recent Revenue History
  • Lifescan Inc
  • Recent Revenue History
  • IP Issues
  • Medtronic Inc
  • Recent Revenue History
  • Nemaura Medical, Inc
  • Nightscout
  • Nipro Diagnostics, Inc
  • Recent Revenue History:
  • Sanofi Diabetes
  • Recent Revenue History
  • Tandem Diabetes Care, Inc
  • Recent Revenue History
  • TypeZero Technologies
  • Verily (formerly Google Life Sciences)

TWENTY-ONE: COMPANY PROFILES: HEMATOLOGY (CELL ANALYSIS) SPECIALISTS

  • CellaVision AB
  • Recent Revenue History
  • Horiba Medical
  • Recent Revenue History
  • Chemistry
  • Medica Corporation
  • Oncascan Limited
  • West Medica
  • Zyomyx Inc

TWENTY-TWO: COMPANY PROFILES: HISTOPATHOLOGY SPECIALISTS

  • Advanced Cell Diagnostics (ACD)
  • Amoy Diagnostics Co. Ltd
  • Applied Spectral Imaging Inc. (ASI)
  • BioGenex Laboratories Inc
  • BioView Ltd
  • Recent Revenue History
  • Circulomics Inc
  • Dako A/S
  • Recent Revenue History
  • Special Stains
  • Immunohistochemistry (ICH)
  • Companion Diagnostics
  • Flow Cytometry
  • Automation
  • Alliances
  • Definiens
  • EMD Millipore
  • HTG Molecular Diagnostics
  • Recent Revenue History
  • Kapa Biosystems Inc
  • Leica Biosystems
  • Collaborations
  • Omnyx LLC
  • Ventana Medical Systems Inc
  • Recent Revenue History
  • Digital Pathology
  • Virtuoso Software Update
  • Product News
  • Automation
  • Partnerships
  • Visiopharm

TWENTY-THREE: COMPANY PROFILES: IMMUNOASSAY SPECIALISTS

  • BG Medicine, Inc
  • Recent Revenue History
  • Binding Site Group Ltd. (The)
  • Recent Revenue History
  • Biohit Oyj
  • Recent Revenue History
  • Market Expansion
  • Biomerica Inc
  • Recent Revenue History
  • Bio-Techne Corporation
  • Recent Revenue History
  • Corgenix Medical Corporation
  • Critical Diagnostics
  • Diaxonhit
  • Recent Revenue History
  • Euroimmun AG
  • Recent Revenue History
  • Hob Biotech
  • Immunodiagnostic Systems (IDS)
  • Recent Revenue History
  • INOVA Diagnostics, Inc
  • Integrated Diagnostics (Indi)
  • One Lambda
  • Recent Revenue History
  • Orgentec Diagnostika
  • Recent Revenue History
  • Protagen Diagnostics
  • Quanterix Corporation
  • Response Biomedical Corp
  • Recent Revenue History
  • Singulex, Inc
  • Theradiag
  • Recent Revenue History
  • VolitionRx Limited

TWENTY-FOUR: COMPANY PROFILES: INFORMATION TECHNOLOGY SPECIALISTS

  • Advaita Bioinformatics
  • Apple Inc
  • Cartagenia
  • Cerner Corp
  • CLC bio
  • Cypher Genomics Inc
  • Dell Healthcare and Life Sciences
  • Desktop Genetics, Ltd
  • DNAnexus
  • Edico Genome
  • Euformatics Oy
  • GENALICE
  • GenomOncology
  • Google Genomics (Alphabet)
  • IBM Healthcare
  • Intel Corporation
  • Knome Inc
  • Collaborations
  • N-of-One
  • PierianDx
  • Rennova Health, Inc
  • Sophia Genetics
  • Sunquest Information Systems
  • Tute Genomics
  • WuXi NextCODE Genomics

TWENTY-FIVE: COMPANY PROFILES: MICROBIOLOGY SPECIALISTS

  • Accelerate Diagnostics, Inc
  • Advanced Biological Laboratories, S.A. (ABL)
  • AdvanDx, Inc
  • altona Diagnostics
  • ArcDia International Oy Ltd
  • BioFire Diagnostics, Inc
  • Recent Revenue History
  • Copan Diagnostics Inc
  • Lab Automation
  • Partnerships
  • Swabs
  • Curetis AG
  • Fast-Track Diagnostics
  • Focus Diagnostics, Inc
  • Genetic Analysis AS
  • GeneWeave Biosciences, Inc
  • About Smarticle Technology
  • Great Basin Scientific, Inc
  • Greiner Bio-One International GmbH
  • Preanalytical Products
  • Hain Lifescience GmbH
  • Meridian Bioscience, Inc
  • Recent Revenue History
  • Immunoassays
  • illumigene
  • Meridian Life Science
  • Sample Collection
  • Mobidiag Ltd
  • Nanosphere, Inc
  • Recent Revenue History
  • Market Expansion
  • PositiveID Corporation
  • Recent Revenue History
  • Seegene, Inc
  • Recent Revenue History
  • Instrumentation
  • Collaborations
  • Specific Technologies
  • Synbiosis Ltd
  • T2 Biosystems
  • Recent Revenue History
  • ViroCyt, LLC

TWENTY-SIX: COMPANY PROFILES: MOLECULAR TEST SPECIALISTS

  • Agena Bioscience
  • Market Expansion
  • Asuragen Inc
  • Controls
  • Sample Collection
  • Sequencing
  • AutoGenomics Inc
  • BGI (formerly Beijing Genome Institute)
  • Prenatal Testing
  • Liquid Biopsy
  • With Complete Genomics
  • BGI Projects
  • Biocartis Group
  • Recent Revenue History
  • Connectivity
  • DMAT Instrumentation - MyCartis
  • Idylla News
  • Infectious Diseases
  • Building the Future
  • Collaborations
  • Enzo Biochem Inc
  • Recent Revenue History
  • IP Situation
  • Epigenomics
  • Exosome Diagnostics, Inc
  • Fluidigm Corporation
  • Recent Revenue History
  • GenMark Diagnostics
  • Recent Revenue History
  • Genome Diagnostics BV (GenDx)
  • Life Technologies Corporation
  • Instrumentation and Applications
  • Liquid Biopsy
  • Sequencing
  • Life Technologies an IVD company
  • Emerging Pathogens
  • Bacterial Typing
  • Forensic
  • Nanostring Technologies, Inc
  • Recent Revenue History
  • Immunohistochemistry
  • Alliances
  • LDTs
  • Oxford Nanopore Technologies Ltd
  • Pacific Biosciences of California, Inc. (PacBio)
  • Recent Revenue History
  • QuanDx Inc
  • RainDance Technologies, Inc
  • Recent Revenue History
  • Market Expansion
  • Rubicon Genomics, Inc
  • Transgenomic, Inc
  • Alliances
  • Lab Services
  • Diagnostic Tools Division
  • TrovaGene, Inc
  • Vela Diagnostics
  • WaferGen Bio-systems, Inc
  • Recent Revenue History

TWENTY-SEVEN: COMPANY PROFILES: POINT OF CARE TEST

  • SPECIALISTS
  • Abaxis, Inc
  • Recent Revenue History
  • Abingdon Health Ltd
  • Atlas Genetics Ltd
  • Biomeme, Inc
  • Chembio Diagnostic Systems, Inc
  • Recent Revenue History
  • DNA Electronics Ltd (DNAe)
  • Enigma Diagnostics Limited
  • Entopsis
  • Epistem Holdings plc
  • FABPulous B.V
  • Fio Corporation
  • Hema Diagnostic Systems (HDS)
  • Imec
  • InSilixa Inc
  • MedMira Inc
  • OraSure Technologies, Inc
  • Recent Revenue History
  • The Genotek Business
  • PTS Diagnostics
  • QloudLab SA
  • QuantuMDx Group Limited
  • Rheonix, Inc
  • Samsung Healthcare
  • Scanadu, Inc
  • Theranos, Inc
  • Veredus Laboratories Pte Ltd
  • Xagenic

TWENTY-EIGHT: COMPANY PROFILES: PRENATAL TEST SERVICE PROVIDERS

  • Ariosa Diagnostics, Inc
  • Berry Genomics Co. Ltd
  • Combimatrix Corp
  • Recent Revenue History
  • Good Start Genetics, Inc
  • Illumina
  • IP Issues
  • Cytogenetics
  • Inex Innovations Exchange
  • LifeCodexx AG
  • MAP Diagnostics Ltd
  • Multiplicom N.V
  • Natera
  • Recent Revenue History
  • Oncology - Planning for the Future
  • Premaitha Health plc
  • Sequenom Inc
  • Recent Revenue History
  • Market Expansion
  • Product Expansion
  • IP Issues
  • Oncology
  • Coagulation

TWENTY-NINE: COMPANY PROFILES: QUALITY CONTROL & SAMPLE PRETREATMENT SPECIALISTS

  • Horizon Discovery Group plc
  • Recent Revenue History
  • Collaborations
  • MO BIO Laboratories, Inc
  • Oasis Diagnostics Corporation
  • PreAnalytiX GmbH
  • SeraCare Life Sciences, Inc
  • Streck Inc

THIRTY: COMPANY PROFILES: TEST SERVICE PROVIDERS

  • 23andMe
  • The Move to Building a Research Company
  • Therapeutics Group
  • Ancestry
  • Outside the U.S
  • Agendia BV
  • Recent Revenue History
  • Ambry Genetics
  • Epilepsy
  • Oncology
  • Cardiac
  • Prenatal
  • Information Technology
  • ARUP Laboratories
  • Assurex Health
  • BioCollective (The)
  • Bio-Reference Laboratories, Inc. (BRLI)
  • bioTheranostics
  • BluePrint Genetics Oy
  • Boston Heart Diagnostics
  • CareDx, Inc. (Formerly XDx, Inc.)
  • Recent Revenue History
  • Sequencing
  • Cleveland HeartLab Inc
  • Counsyl
  • Eurofins Genomics
  • Exact Sciences Corp
  • Recent Revenue History
  • Foundation Medicine Inc
  • Recent Revenue History
  • Collaborations
  • Genomic Health, Inc
  • Recent Revenue History
  • Market Uptake
  • Liquid Biopsy
  • Service Spin-off
  • Genomic Vision
  • Recent Revenue History
  • Helomics Corporation (formerly Precision Therapeutics, Inc)
  • Mayo Medical Laboratories
  • Information Technology
  • MDxHealth SA
  • Recent Revenue History
  • OPKO Diagnostics
  • Pathway Genomics Corporation
  • Rosetta Genomics Ltd
  • Recent Revenue History
  • Expansion
  • Sonic Healthcare
  • Recent Revenue History
  • Veracyte, Inc
  • Recent Revenue History
  • Vermillion Inc
  • Recent Revenue History

List of Exhibits

ONE: EXECUTIVE SUMMARY

  • Table 1-1: Exchange Rate Fluctuations, 2012-2016
  • Table 1-2: Worldwide In Vitro Diagnostic Reagent Sales by Market Segment, 2016-2021

TWO: INTRODUCTION

  • Table 2-1: Worldwide In Vitro Diagnostic Sales by Product Market, 2016-2021
  • Table 2-2: Selected Diagnostics Industry Acquisitions, 2014, 2015 and H2 2016
  • Table 2-3: Selected Diagnostics Industry Distribution Agreements, 2014, 2015, H2 2016
  • Table 2-4: Selected IVD collaboration/Licensing Agreements, 2014, 2015, H2 2016
  • Table 2-5: Selected Test Services, Sales 2012-2016
  • Table 2-6: Lab Market Segmentation, Worldwide, 2016
  • Table 2-7: Revenues for a Selection of U.S.-based Reference Labs, 2012-2016
  • Table 2-8: Selected Company sponsored Labs Established in 2014 and 2015
  • Table 2-9: Revenues of Selected Top IVD Companies, 2012-2016
  • Table 2-10: Revenues of Selected Niche Players, 2012-2016
  • Table 2-11: IVD Test Segment Sales 1995-2015

THREE: OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC MARKETS

  • Table 3-1: World Population Distribution, 2016
  • Table 3-2: Selected Disease Statistics, Worldwide
  • Table 3-3: Elderly Support Ratio in Selected Countries (2050)
  • Table 3-4: Available Market Data, 2016
  • Table 3-5: Worldwide In Vitro Diagnostic Reagent Sales by Country/Region, 2016-2021
  • Figure 3-1: EU IVD Revenue Stream 2007-2016
  • Table 3-6: European Union (EU14) IVD Sales by Country 2014
  • Table 3-7: Per Capita IVD Expenditure

FOUR: TRENDS AND INNOVATION

  • Table 4-1: Selected Sequencing Platforms
  • Table 4-2: Selected IVD industry IT Investments
  • Table 4-3: Selected Gene Editing Research Kits
  • Table 4-4: Selected Wearable Devices
  • Table 4-5: Selected Disease Markers in Exhaled Breath
  • Table 4-6: Selected Breath Test Innovations

FIVE: POINT-OF-CARE TESTS

  • Table 5-1: Professional POC Test Sales by Category, Worldwide, 2016-2021
  • Table 5-2: Hospital POC Test Usage, U.S
  • Table 5-3: Selected Profession POC Test Innovations
  • Table 5-4: POC Self Test Sales by Category, Worldwide, 2016-2021
  • Table 5-5: POC Test Revenues of Selected IVD Companies, 2013-2015
  • Table 5-6: Selected Apps and Glucose Management IT
  • Table 5-7: Diabetes Sales by Test Category, Worldwide, 2016-2021
  • Table 5-8: World Glucose Monitoring Sales, Major Companies, 2012-2016
  • Table 5-9: Selected Glucose Self-Test Meter Innovations
  • Table 5-10: Selected Noninvasive Glucose Monitoring Devices
  • Table 5-11: Selected Continuous BGM Sales, 2013 - 2016
  • Table 5-12: Selected Continuous Blood Glucose System Developments
  • Table 5-13: Selected Innovations in Hospital-based Glucose Monitoring
  • Table 5-14: Selected POC HbA1c Devices
  • Table 5-15: Selected POC Diabetes Monitoring Tests

SIX: THE CORE LAB

  • Table 6-1: Workstation Sales, 2016-2021 (General Chemistries, Immunos on workstations)
  • Table 6-2: Core Lab Sales of the Top Five Manufacturers, 2012-2016
  • Table 6-3: Selected New Analytes for the Core Lab, 2014-2015
  • Table 6-4: Selected Lab Automation Innovations
  • Table 6-5: Worldwide Clinical Chemistry Sales by Test Category, 2016-2021
  • Table 6-6: Major Clinical Chemistry Companies
  • Table 6-7: Selected Clinical Chemistry Innovations
  • Table 6-8: Major Whole Blood Chemistry Analyzers
  • Table 6-9: Selected Apps, Critical Care and Urinalysis IT Innovations, 2016
  • Table 6-10: Selected Urinalysis Innovations, 2016

SEVEN: IMMUNOASSAYS

  • Table 7-1: Selected New Immunoassay Technologies, 2016
  • Table 7-2: Selected Innovation in Mass Spectrometry for Routine Analyses
  • Table 7-3: Selected Immunoassay Innovations on Core Lab Instruments
  • Table 7-4: Worldwide Lab-based Immunoassay Sales by Analyte Type, 2016-2021
  • Table 7-5: Selected Immunoassay Quality Control Products
  • Table 7-6: Revenue History of Leading Immunoassay Vendors, 2012-2016
  • Table 7-7: Selected New Vitamin D Immunoassays, 2014-2016
  • Table 7-8: Selected Tumor Marker Innovations, 2014-2016
  • Table 7-9: Selected Cardiac Marker Innovations
  • Table 7-10: Selected Autoimmune Test Innovations
  • Table 7-11: Selected Arthritis Immunoassay Innovations
  • Table 7-12: Selected Inflammatory Bowel Disease Test Innovations
  • Table 7-13: Selected Immunoassays for Transplant Medicine
  • Table 7-14: Selected Women's Health Innovations
  • Table 7-15: Selected Innovations for Alzheimer's Disease Immunoassays
  • Table 7-16: Selected Immunoassay Innovations
  • Table 7-17: POC Immunoassay Test Sales by Test Category, 2016-2021
  • Table 7-18: Selected Self-Test Immunoassay Innovations
  • Table 7-19: Selected Professional POC Test Innovations, 2016
  • Table 7-20: Selected POC Immunoassay Test Platforms

EIGHT: MOLECULAR ASSAYS 310

  • Table 8-1: Common Next Generation Molecular Test Traits
  • Table 8-2: Selected Molecular Test Sample Preparation and QC Innovations
  • Table 8-3: Selected Exosome Test Innovations
  • Table 8-4: Selected Liquid Biopsy Innovations
  • Table 8-5: Selected IT Innovations in Molecular Diagnostics
  • Table 8-6: Selected Innovations in Forensic DNA Testing
  • Table 8-7: Key Molecular Technologies and Major Players
  • Table 8-8: Selected Molecular Test Platform Innovations
  • Table 8-9: Molecular Test Revenues of Selected IVD Vendors, 2012-2016
  • Table 8-10: Worldwide Molecular Test Sales by Type, 2016-2021
  • Table 8-11: Selected Molecular Tumor Marker Test Innovations
  • Table 8-12: Most Frequently Requested Genetic Tests
  • Table 8-13: Selected Genomic Tests for Inherited Diseases
  • Table 8-14: Revenue Stream of Selected NIPT Service Companies, 2012-2015
  • Table 8-15: Prenatal Services Provided
  • Table 8-16: Selected Molecular Tests for Prenatal Analysis
  • Table 8-17: Selected HLA Typing Test Innovations

NINE: HEMATOLOGY

  • Table 9-1: CellaVision Placement Data by Hematology Vendor
  • Table 9-2: Selected Hematology Image Analysis Innovations, 2014-2015
  • Table 9-3: Selected POC Hematology Innovations
  • Table 9-4: Revenue History of the Major Hematology Vendors, 2012-2016
  • Table 9-5: Selected Hematology Innovations, 2016

TEN: COAGULATION

  • Table 10-1: Worldwide Coagulation Sales by Segment, 2016-2021
  • Table 10-2: Selected Lab-based Coagulation Innovations, 2016
  • Table 10-3: Selected Molecular Coagulation Test Innovations
  • Table 10-4: Selected POC Coagulation Test Innovations
  • Table 10-5: Top Coagulation Company Revenues, Lab & POC, 2012 - 2016
  • Table 10-6: Major Anticoagulants Uses and Tests

ELEVEN: MICROBIOLOGY AND VIROLOGY

  • Table 11-1: Global Deaths from Communicable Diseases, 2010
  • Table 11-2: Selected Tests for Emerging Pathogens
  • Table 11-3: Selected Tests for Antibiotic Resistance
  • Table 11-4: Selected Microbiology Mass Spec Innovations
  • Table 11-5: Selected Microbiome-based Tests
  • Table 11-6: Worldwide Microbiology/Virology Sales by Type, 2016-2021
  • Table 11-7: Selected Innovations in Microbiology Pre-Analytical Products
  • Table 11-8: Selected Innovations in Bacterial Identification
  • Table 11-9: Selected Antibiotic Sensitivity Test Innovations
  • Table 11-10: Revenue of Selected Microbiology Companies, 2013, 2016
  • Table 11-11: Selected Advanced Techniques for Positive Blood Cultures
  • Table 11-12: Lab-based Infectious Disease Immunoassays, by Test, 2016
  • Table 11-13: Selected Infectious Disease Immunoassay Innovations
  • Table 11-14: Selected Professional Use POC Tests for Infectious Diseases
  • Table 11- 15: Selected Molecular Test Platform Innovations, 2014-2016
  • Table 11-16: Selected Microbiology Sequencing Innovations
  • Table 11-17: Molecular Test Sales, Infectious Diseases, 2016
  • Table 11-18: Selected Molecular HAI Test Innovations
  • Table 11-19: Selected Molecular Tests for STDs
  • Table 11-20: Selected Molecular Respiratory Disease Innovations
  • Table 11-21: Selected Molecular HIV Test Innovations
  • Table 11-22: Selected Infectious Disease Molecular Test Innovations
  • Table 11-23: Selected Molecular POC Device Innovations

TWELVE: BLOOD BANKING SERVICES

  • Table 12-1: Blood Donation, Key Facts
  • Table 12-2: Distribution of Blood Units Collected
  • Table 12-3: Laboratory Screening of Blood Donations for Transfusion-Transmissible Infections, Number of Countries (Syphilis, HCV, HBV, HIV)
  • Table 12-4: Blood Component Usage (Liver Transplant, Adult Open Heart Surgery, Automobile Accident, Leukemia, Sickle Cell Disease, Cancer Chemotherapy)
  • Table 12-5: Impact of Alloimmunization (% of Patients Screening Positive for One or More Antibodies)
  • Table 12-6: Worldwide Blood Bank Sales, 2016-2021
  • Table 12-7: Selected Blood Grouping Innovations
  • Table 12-8: Selected New Blood Screen NAT Tests and Systems

THIRTEEN: HISTOLOGY AND CYTOLOGY

  • Table 13-1: Selected Histology Lab Automation
  • Table 13-2: Histology Information Technology Tools
  • Table 13-3: Selected Advanced Histology Techniques
  • Table 13-4: Selected HPV Test Innovations
  • Table 13-5: Worldwide Histology/Cytology Sales by Type, 2016-2021
  • Table 13-6: Revenues of the Major Histology Companies, 2012-2016
  • Table 13-7: Selected Vendors Of Traditional Histology Stains
Back to Top